Introduction
Angioimmunoblastic T-cell lymphoma (AITL), one of the most frequent peripheral T-cell lymphoma (PTCL), 1 usually affects elderly patients in their 6th or 7th decade. 2 It is clinically characterized by widespread lymphadenopathy, and commonly, extranodal disease, immunemediated hemolysis, and polyclonal hypergammaglobulinemia. 3 The recent identification of follicular helper T cell (TFH) as the cell of origin of this lymphoma 4, 5 represents a major step in the understanding of the clinicobiological characteristics of the disease. 6 This T-cell subset promotes positive selection, proliferation and differentiation of germinal center antigenspecific B-cells. 7 The TFH derivation of AITL provides a rationale to explain the common expansion of B cells, the plasmacytic infiltrate in tumor biopsies, and the hypergammaglobulinemia as well as the dysimmune manifestations of the disease. 8 The clinical course of AITL is variable, with occasional spontaneous remissions, but overall its prognosis is poor with a median overall survival less than 3 years in most studies. 6 Various treatment strategies ranging from watch and wait attitude to the combination of chemotherapeutic agents have proved largely insufficient. Different combination of chemotherapies, such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
or CHOP-like regimens have failed to increase the survival rate to more than 35% at 5 years. 9, 2 Several attempts to add drugs to CHOP, as etoposide 10 and bleomycin in the MACOP-B, 11 also revealed unsuccessful. In a GELA large retrospective study of AITL patients who had been enrolled into different therapeutic protocols, 2 no positive impact on survival was observed for any treatment, even for patients submitted to a consolidation with autologous stem cell transplantation (ASCT). For younger and fitter patients the indication of consolidative ASCT remains under debate 12, 13 but alternative strategies have to be developed for elderly patients.
One peculiar pathological feature of AITL is the highly variable proportion of neoplastic T cells, sometimes minor, compared to the reactive component made up of small lymphocytes, histiocytes, eosinophils, plasma cells, and B immunoblasts, suggesting a role of the microenvironment in maintenance of tumor cells viability. EBV infected B-blasts are detected in most AITL. 14 The biological significance and pathophysiological implications of this observation is still unclear. EBV infection/reactivation can occur as a consequence of an underlying "immune dysfunction", but no correlation between EBV and immune parameters has been documented in AITL. EBV may, through the modulation of cytokines, chemokines and membrane receptors, play a paracrine role either on the development of the tumor microenvironment, 15 or on tumor cell survival, ultimately favoring disease progression.
Taking into account both the B-cell hyperstimulation stigmata associated to an increased B-cell number present in tumor tissue of AITL and the putative feeder role of B-cell or EBV-infected B-cells for neoplastic T-cells, we postulated that AITL patients might benefit from a treatment with anti-CD20 monoclonal antibody (Rituximab) in synergy with an anthracyclin-containing chemotherapy. We report here the results of a phase II clinical trial where patients aged 60 to 80 years with newly diagnosed AITL were treated by a combination of Rituximab and CHOP (R-CHOP). The pathological features of the tumors and the clinically relevant immunobiological and viral parameters were analyzed in detail and correlated to the clinical features.
Design and Methods

Study Design
The study was a multicentric, phase II, open-label, non-randomized trial evaluating the efficacy of R-CHOP, delivered every 3 weeks, in patients aged 60 to 80 years with a first diagnosis of AITL. Patients were enrolled in 11 participating centers of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Patients were eligible if not previously treated (except steroids providing they had been initiated less than 10 days before inclusion) with a good performance status (ECOG PS ≤ 2).
Additional eligibility requirements included unaltered renal and hepatic functions, and adequate bone marrow reserve (neutrophils > 1.5 X10 9 /L and platelets >100X10 9 /L) unless alterations were related to the disease. Non-eligibility criteria included contra-indication to any drug included in the R-CHOP regimen, a life expectancy inferior to 3 months, central nervous system or meningeal involvement by lymphoma. Patients with human immunodeficiency virus infection or an active hepatitis B or hepatitis C infection were also excluded as were subjects with previous history of cancer (except an adequately treated non-melanoma skin cancer or in situ cervical cancer) during the last 5 years.
Initial staging included physical examination, standard laboratory assessments, Coombs test, gammaglobulin levels, computed tomography (CT) scans of the chest, abdomen and pelvis, and a bone marrow biopsy. additional cycles. G-CSF support was not planned. In case of severe neutropenia or neutropenia related infection, sub-cutaneous GCSF was recommended from day 6 to day 13 or until neutrophils ≥ 1.0G/l, for subsequent cycles.
Study management
The GELA acted as the sponsor of the study. On-site monitoring was organized in each center.
All case report forms were sent to the GELA central operation office (GELA-RC) and double data entry was undertaken for verification purposes. Outliers and erroneous values were checked routinely. Queries and on-site monitoring data were used for final validation, and GELA-RC had full control of the database. Statistical analyses were performed by statistical department of GELA-RC.
The protocol was approved by local ethic committee according to the French laws and the study was conducted in accordance with the Declaration of Helsinki. Patients were required to provide written informed consent prior to registration. The study is registered with clinicaltrials.gov (NCT00169156) and had the EudraCT number 2005-002602-37.
Toxicity and Response Assessments
Hematological and non-hematological toxicities were graded according to the National Cancer Follow-up assessments included clinical evaluation every 3 months and CT scans every 6 months for an additional 3-year period.
Histological and Immunohistochemical analyses and scoring.
Pathological specimens were centrally reviewed in the GELA-Pathology institute (GELA-P) and diagnosis of AITL was confirmed by at least 2 expert hematopathologists based on the criteria of the WHO classification. 1 Slides were stained with hematoxylin-eosin and Giemsa and with an appropriate panel of antibodies directed against B-(CD20, CD79a), T-(CD3, CD2, CD5, CD7, CD4), follicular dendritic cell (FDC) antigens, CD10 17 and TFH-associated molecules, (PD1, CXCL13), as previously described. 18 The diagnosis was based on the following criteria: partial or diffuse effacement of the nodal architecture, polymorphous cellular infiltrate, vascular proliferation with prominent arborization of high endothelial venules, extrafollicular meshwork of FDCs, atypical population of CD3 + T cells, and presence of large CD20 + B-cells blasts with or without evidence of EBV infection. Cases were classified according to the 3 patterns described by Attygale. 17 The presence of EBV was investigated by in situ hybridization with probes specific for the EBV-encoded small RNA (EBER1 and 2) sequences. Lymphocytes subpopulations were analyzed by Flow cytometry on diagnostic fresh samples (see below). Plasma was aliquot to 1 ml vials and stored at -80°C for further analyses.
Mononuclear cells (PBMC) were isolated from 40ml peripheral blood by Ficoll-hypaque density gradient centrifugation, dispatched to 10 million pellets cells aliquots and stored at -80°C. Frozen or fixed and paraffin embedded sections of lymph node were referred for DNA extraction.
DNA extraction
DNA was obtained from lymph node samples using a standard proteinase K digestion and a phenol/chloroform extraction. PBMC DNA were obtained from frozen pellets using by qiasymphony automated extraction (Qiagen®). Plasma samples DNA extractions were performed by means of QIAamp DNA blood minikit from Qiagen®.
Flow cytometry
Absolute counts of T CD4 (CD3+ CD4+), T CD8 (CD3+ CD8+), and B (CD19+) peripheral blood lymphocytes subsets, were obtained directly using Cyto-Stat tetraCHROME™ (Beckman-Coulter). The presence of circulating tumoral T cells was assessed by at least one of the following criteria (i) CD3-CD4+ immunophenotype 19 (ii) total or partial loss of pan-T antigens CD2, CD5, or CD7, using a combination of CD2-FITC, CD7-RD1, CD3-ECD, CD4-TRI, CD5-PC7; (iii) coexpression of CD10. 20 All antibodies were from Beckman-Coulter.
Flow Cytometry was performed on a Coulter FC500 within 24 hours after staining. Listmode parameters were analyzed and stored on the software CXP™ (Beckman-Coulter).
Normal values were as follow: 21 
B and T lymphocyte clonality analyses
T-cell receptor (TCR) gamma chain gene analysis was performed by GC-clamp multiplex PCR and Denaturing Gradient Gel Electrophoresis (DGGE) as previously described. 22 A dominant peripheral blood T-cell clone was considered as tumoral when the same DGGE imprint could be documented in the tumoral lymph node. 23 For Immunoglobulin heavy (FR1/JH, FR2/JH, FR3/JH), and light (IGK, IGKDE) chain gene rearrangement studies, PCR were performed according to Biomed 2 protocol. 24 Samples with a unique intense or weak dominant peak within the polyclonal background were considered as clonal, those with multiple dominant peaks as oligoclonal and those with a polyclonal pattern as non-clonal.
EBV status: genome detection and quantification, serology
EBV DNA amplifications were performed using Mix fast DNA LC (Roche Molecular Systems®) and analyzed in real-time on the Light Cycler system (Roche Molecular Systems®). A sequence of 169 bp from the BXLF1 gene coding for the viral thymidine kinase was amplified using primers and probes described by Brengel-Pesce et al. 25 EBV DNA quantification was performed by means of an external standard curve constructed using 10 fold dilutions of a plasmidic DNA containing the 169 bp fragment. Results were expressed as number of copies per mL of plasma or per µ g of PBMC DNA by means of β-globin quantification. Specific anti-EBV antibodies (IgG anti-VCA, IgG anti-EBNA and IgM anti-VCA) were sought in serum samples using LIAISON® kits (Liaison® EBV VCA IgG, Liaison® EBV VCA IgM and Liaison® EBV EBNA).
Statistical Methods
The primary endpoint was complete response rate, including complete response and unconfirmed complete response at the end of treatment. Previous studies using CHOP reported an overall response rate estimated to 40% in patients with AITL. 26 In order to detect an overall response rate higher than 40% after 8 cycles of R-CHOP, we calculated using a triangular test procedure every 5 patients that a sample size of 25 assessable patients recruited over 2 years would provide 80% power at an overall 5% (2-sided) significance level. As one of secondary endpoints, Progression-Free survival (PFS) was measured from date of inclusion to date of progression/relapse or death from any cause. Overall survival (OS) was calculated from the date of enrollment until death from any cause.
PFS and OS were estimated using the product-limit method of Kaplan-Meier and compared using the log-rank test on intent to treat basis and data were censored at the date of last evaluation when the stopping date (September 1, 2009) was not reached. Correlation between response rate and patient characteristics and biological data (circulating lymphocyte phenotype, EBV status, T/B clonality) were performed using the Fisher exact test. Statistical tests were considered significant when the two-sided P-value was < .05. Confidence intervals (CIs) were computed with a 95% coverage; 95% CI binomial exact bounds were computed for proportions. All statistical analyses were performed using SAS software (Version 8.2; SAS Institute, Cary, NC, USA).
Results
Patients
Clinical presentation
Between December 2005 and January 2008, 27 patients were enrolled and 25 were eligible for analysis: two patients were withdrawn before receiving any treatment, one retracted his informed consent and another had active hepatitis B. Pretreatment patient characteristics are summarized in Table 1 . Median age was 68 years (range, 60 to 79 years). Patients had all an extended disease including 22 (88%) stage IV. Seventeen patients (68%) presented with more than one involved extranodal site.
Pathological presentation
The pathological review process confirmed histopathological and immunophenotypic features of AITL in all cases. They corresponded to pattern III AITL with diffuse infiltration in most Table 2 ).
Flow cytometry was performed on peripheral blood in 21/25 patients. A highly variable absolute lymphocyte count was found ( Figure 3A) . The most frequent quantitative abnormality was T-cell lymphopenia (CD3+ <600 mm3) in 10/21 (47%) patients. It was related to a single subset deficiency, CD4 (n=3), or CD8+ (n=1), but more frequently to both (n=6). The same variability was found in B-cell compartment, with often profound deficiency (<20/mm3, n=9) mostly associated with CD3+ deficiency (n=5). (For detail per patients, see supplementary Figure 3B ). Detection of circulating tumor cells was not related to bone marrow infiltration or tumor cell density in the diagnostic lymph node.
EBV status in peripheral blood at diagnosis
Anti-VCA and anti-EBNA IgG were positive for 17/19 and 15/19 patients respectively. EBV genome was found in PBMC in 14 out of 22 studied patients (median 1.10 3 cp/ PBMC µg; range 6.10 0 to 5.10 4 ). This EBV detection highly correlated with EBV quantification by EBER-ISH in lymph node biopsies (all patients with EBV in PBMC < 100 copies/µg DNA had an EBER ISH score <1, p=0.004) ( Figure 4A ).
EBV DNA normally lies inside circulating B lymphocytes, whereas patients with active EBV replication also have detectable viral DNA in plasma. 27 We thus decided to quantify EBV genome in plasma. Out of 20 tested patients, 8 had detectable EBV DNA, including 5 with more than 1000 copies per ml plasma (Supplementary Table 3 ). Of note, one patient with negative EBV detection in lymph node, PBMC and sera had a negative anti EBV serology.
EBV genome in PBMC or in plasma was not associated with CD3+ lymphopenia, neither with deficiency of CD4+ or CD8+ subsets ( Figure 4B ). By contrast, the presence of circulating EBV genome was highly correlated with the presence of circulating tumor cells (p= 0.0019) ( Figure   4C ).
Treatment exposure and toxicities
Four patients stopped treatment prematurely, two for toxic death (one septicemia after cycle 2 and one septicemia with intestinal perforation after cycle 3), one for disease progression (after cycle 4) and one after physician decision (partial response after cycle 4). As a result, 21
patients (84%) completed the planned 8 cycles, most of them receiving their treatment on an outpatient basis. The most common adverse events were represented by hematological toxicity.
Grade 3-4 neutropenia and thrombocytopenia were reported in 72% and 25% respectively during the first 4 cycles and in 60% and 4% during the subsequent 4 cycles. Accordingly, 21
patients required G-CSF. Only 6 documented infections during neutropenia periods were observed. To note, 14 of the 22 (64%) serious adverse events declared in 9 patients were related to infections. One additional toxic death due to a chronic inflammatory demyelinating polyradiculoneuropathy was observed 5 months after the end of treatment, leading to a total number of 3 toxic deaths.
Clinical outcome
Response at the end of treatment was assessed after treatment completion for 21 patients and at premature withdrawal for 4 patients. Eleven patients had achieved a CR/CRu (44%; 95% CI, 24% to 65%). Nine patients (36%) had a partial response, 2 patients progressed, and 3 died including one with progressive lymphoma, leading to an overall response rate of 80% (CI, 59% to 93%). The median response duration was 25 months for patients achieving CR/CRu (13.5-NR).
With a median follow-up of 24 months (range from 2 to 38 months), the 2-year PFS rate was 42% (95% CI, 22% to 61%) ( Figure 5A ) and overall survival rate was 62% (95% CI, 40% to 78%) ( Figure 5B). Six of the 9 deaths that occurred between end of treatment and stopping date were attributed to lymphoma. Of note, no patients developed diffuse large B cell lymphoma during the follow-up period, although some of them had sheets/clusters of B-Blasts.
Clinicobiological correlations
A relationship between Rituximab-targeted cells evaluated at diagnosis and clinical outcome was determined. In univariate analysis, B blast density in tumor biopsy had no influence on clinical outcome including response rate (Table 2) . Although the detection of EBV copies in PBMC was not associated with response to treatment (p=0.6), (Table 2) , it tended to be associated with a shorter PFS (logrank p=0.06) ( Figure 6 , Table 2 ). The circulating EBV was reviewed after treatment in 11 patients, 5 of whom were positive at diagnosis. A negative conversion was observed in 4 patients of whom 3 were in CR/Cru. The patient who remained positive was in partial response. Of note, out of the 6 EBV negative patients at diagnosis, only one converted to positive after treatment and was in partial response.
The close relationship between circulating EBV and circulating tumor cells prompted us to look for prognostic value of circulating tumor cells before treatment. The detection of circulating tended to correlate with a poor response to treatment (75% of non-responders had detectable CTC (p= 0.08)). However, in this limited series, it did not translate significantly into a worse PFS (logrank p= 0.17) nor survival (logrank p=0.8).
Discussion
In this trial, Rituximab combined to CHOP regimen allows reaching a high overall response rate (80%), including complete response in 44% elderly patients with AITL. Our goal was to target CD20-positive cells including EBV infected B-blasts present in most AITL tumors that might play a feeder role for tumor cell survival in lymph nodes. The hypothesis remains pertinent with regard to the recently published data showing that intrafollicular maintenance of the TFH phenotype requires the continued presence of antigen-specific B cells. 28, 29 However, in the absence of published data focusing specifically on AITL -and not on the more heterogeneous group of PTCLs -and more specifically on AITL patients over 60 treated with chemotherapy, it remains difficult to speculate on the potential benefit of R-CHOP in this small cohort. In the statistical design of the study, we might have overestimated the response to CHOP we referred to in this elderly population (40 to 45% of RC / RCU).
Nevertheless, the response duration observed in this series is short and the PFS is quite disappointing and close to the one previously reported with CHOP alone. 2 As previously reported, 14 we found EBV genome in the great majority of tumor samples. This observation has been proposed as a strong argument for a pathophysiological driver role of EBV in AITL. 6 In contrast, our results demonstrate that AITL can develop in the absence of EBV. Indeed, one patient disclosed a negative EBV serology, in addition to the absence of EBV genome detected in tumor tissue and blood. In another model, the presence of EBV is the consequence of immune deficiency. Arguments for immunodeficiency are the frequency of infections that are a common cause of death and the occurrence of EBV associated B-cell proliferations in AITL patients. 37, 38 However, immune status yet has not been well characterized in AITL. Here, we determined the CD4+ and CD8+ T-cell counts and correlated their absolute values to EBV status, either in the tumor or in periphery. We found a high frequency of lymphopenia (either CD4+ or CD8+), but an absence of correlation with EBV status, either in the tumor, or in PBMC, and, more relevant regarding immunodeficiency, in sera. Given the demonstration that normal TFH cells could exert immunosuppressive functions on CD4+ TH1 cells, 39 it is possible that immune deficiency in AITL could at least in part be related to the suppressive activity of tumoral TFH. If we speculate that the detection of circulating tumor cells reflects a high tumor load, the suppressive activity of tumoral TFH could explain the intriguing close relationship that we observed between circulating EBV and circulating tumor cells (p=0.001).
We have recently shown that the number of T regulatory cells (Treg) was significantly decreased in AITL lymph nodes compared with follicular lymphoma and reactive lymph node. 40 Interestingly, two recent reports 41 
